Authored Content

Medicaid redeterminations will bring changes to individual prescription drug access. Manufacturers should consider the impact on patient support programs.

Clarifications in the PIE Act may shift manufacturer-payer engagement strategy and improve coverage and reimbursement of new drugs and devices.

Recent Medicare rulemaking requested stakeholder feedback on potential payment system changes to support access to therapies for patients on dialysis.